COGNITIVE PROCESSING THERAPY VERSUS MEDICATION FOR THE TREATMENT OF COMORBID SUBSTANCE USE DISORDER AND POST-TRAUMATIC STRESS DISORDER IN EGYPTIAN PATIENTS (RANDOMIZED CLINICAL TRIAL)

Earlier research has established that posttraumatic stress disorder (PTSD) and substance use disorder (SUD) frequently coexist. Aims: Cognitive Processing Therapy was compared to Sertraline and a placebo in an RCT for treating patients with comorbid SUD and PTSD. Methods: 150 patients with SUD and PTSD were interviewed by clinicians and asked to fill out the Clinician-Administered PTSD Scale (CAPS-5), Posttraumatic Stress Disorder Checklist (PCL-5), Beck Depression Inventory (BDI-II), Timeline Follow Back Interview (TLFB), and Brief Addiction Monitor (BAM). Patients were randomly assigned to the following conditions: CPT (n=50), Sertraline (n=50), or Placebo (n=50). Pretreatment, posttreatment, six and, twelve-month follow-up assessments were conducted. Results: When compared to the sertraline group, CPT resulted in much higher reductions in CAPS scores at posttreatment assessment (d=0.93, p <.000). When compared to the control group, CPT considerably reduced PTSD symptoms (the effect size, d=1.9, p <.000). Sertraline resulted in many significant decreases in CAPS when compared to control groups (the effect size, d=1.11, p <.000). At posttreatment, SUD and depression severity were significantly reduced in both CPT and Sertraline groups. After six and twelve months of follow-up, these differences persisted. Conclusion: Comparatively to the control group, CPT and Sertraline significantly decreased PTSD, SUD, and depression.